Quadrivalent Human Papillomavirus Vaccine Effectiveness: A Swedish National Cohort Study

Evidence of Human Papillomavirus Vaccine Effectiveness in Reducing Genital Warts: An Analysis of California Public Family Planning Administrative Claims Data, 2007–2010

(2012) Heidi M. Bauer et al.   AMERICAN JOURNAL OF PUBLIC HEALTH

Incidence of Genital Warts in Sweden Before and After Quadrivalent Human Papillomavirus Vaccine Availability

(2012) A. Leval et al.   JOURNAL OF INFECTIOUS DISEASES

External review and validation of the Swedish national inpatient register

(2011) Jonas F Ludvigsson et al.   BMC PUBLIC HEALTH

End-of-study safety, immunogenicity and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24–45 years of age

(2011) X Castellsagué et al.   BRITISH JOURNAL OF CANCER

Population Effectiveness, Not Efficacy, Should Decide Who Gets Vaccinated Against Human Papillomavirus via Publicly Funded Programs

(2011) P. E. Castle et al.   JOURNAL OF INFECTIOUS DISEASES

The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme

(2011) T. R. H. Read et al.   SEXUALLY TRANSMITTED INFECTIONS

Vaccine Epidemiology: Efficacy, Effectiveness, and the Translational Research Roadmap

(2010) Geoffrey A. Weinberg et al.   JOURNAL OF INFECTIOUS DISEASES

Impact of Human Papillomavirus (HPV)-6/11/16/18 Vaccine on All HPV-Associated Genital Diseases in Young Women

(2010) Nubia Muñoz et al.   JNCI-Journal of the National Cancer Institute

Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data

(2010) Basil Donovan et al.   LANCET INFECTIOUS DISEASES

The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research

(2009) Jonas F. Ludvigsson et al.   EUROPEAN JOURNAL OF EPIDEMIOLOGY

Attitudes to HPV vaccination among parents of children aged 12-15 years—A population-based survey in Sweden

(2009) Lisen A. Dahlström et al.   INTERNATIONAL JOURNAL OF CANCER

Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24–45 years: a randomised, double-blind trial

(2009) Nubia Muñoz et al.   LANCET